stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) EPS (diluted)
CareDx, Inc.'s EPS (diluted) for fiscal 2025 was −$0.40, compared with $0.93 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.39. Over the past ten years it has ranged from −$3.54 (fiscal 2023) to $0.93 (fiscal 2024); the current reading is higher than 91% of that period. CareDx, Inc. ranks 13th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.40 | — |
| FY2024 | $0.93 | — |
| FY2023 | −$3.54 | — |
| FY2022 | −$1.44 | — |
| FY2021 | −$0.59 | — |
| FY2020 | −$0.40 | — |
| FY2019 | −$0.52 | — |
| FY2018 | −$1.31 | — |
| FY2017 | −$2.38 | — |
| FY2016 | −$2.39 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.35 | (83.09%) |
| Jun 2026 | $2.07 | 4,040.00% |
| Mar 2026 | $0.05 | — |
| Dec 2025 | −$0.08 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| CDNA CareDx, Inc. | $2.39 |
| VCYT Veracyte, Inc. compare | $1.55 |
| BLLN BillionToOne, Inc. compare | $0.92 |
| SHC Sotera Health Company compare | $0.60 |
| NEO NeoGenomics, Inc. compare | −$0.25 |
| RDNT RadNet, Inc. compare | −$0.27 |
| ADPT Adaptive Biotechnologies Corporation compare | −$0.45 |
| WGS GeneDx Holdings Corp. compare | −$3.64 |
| GRAL GRAIL, Inc. compare | −$9.50 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on CDNA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement